Molecular structure of Zoledronic acid monohydrate, CAS Number: 165800-06-6
Zoledronic acid monohydrate (CAS 165800-06-6)
See product citations (5)
Alternate Names:
Zoledronic acid
Application:
Zoledronic acid monohydrate is a highly potent bisphosphonate and activator of PKC
CAS Number:
165800-06-6
Purity:
>98%
Molecular Weight:
290.10
Molecular Formula:
C5H10N2O7P2•H2O
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Zoledronic acid monohydrate is a bisphosphonate compound. It is a potent inhibitor of bone resorption and is used in studies related to osteoporosis and bone metastasis. Zoledronic acid monohydrate is known for its ability to bind to bone mineral and inhibit the activity of osteoclasts, the cells responsible for bone resorption. Zoledronic acid monohydrate has a high affinity for bone tissue and is used in in vitro experiments to investigate the molecular mechanisms of bone metabolism. Zoledronic acid monohydrate is in the study of bone physiology and pathology. Its ability to target bone tissue makes it an important compound for understanding the processes involved in bone resorption and formation.
Zoledronic acid monohydrate (CAS 165800-06-6) References
- Intravenous zoledronic acid in postmenopausal women with low bone mineral density. | Reid, IR., et al. 2002. N Engl J Med. 346: 653-61. PMID: 11870242
- A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. | Saad, F., et al. 2002. J Natl Cancer Inst. 94: 1458-68. PMID: 12359855
- Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. | Legay, F., et al. 2002. J Pharm Biomed Anal. 30: 897-911. PMID: 12408879
- A validated stability indicating ion-pair RP-LC method for zoledronic acid. | Rao, BM., et al. 2005. J Pharm Biomed Anal. 39: 781-90. PMID: 15922532
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. | Black, DM., et al. 2007. N Engl J Med. 356: 1809-22. PMID: 17476007
- Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. | Veltman, JD., et al. 2010. Br J Cancer. 103: 629-41. PMID: 20664588
- Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. | Iranikhah, M., et al. 2012. Pharmacotherapy. 32: 274-84. PMID: 22392458
- Prescribing of zoledronic acid in a tertiary outpatient hospital setting. | Anglada-Martínez, H., et al. 2012. Int J Clin Pharm. 34: 832-6. PMID: 22956210
- YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. | Miwa, A., et al. 2012. Am J Hematol. 87: 1084-8. PMID: 23044853
- The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy. | Karaköse, A., et al. 2014. Curr Urol. 7: 181-4. PMID: 26195947
- In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method. | Li, X., et al. 2017. Int J Pharm. 526: 69-76. PMID: 28455136
- Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. | Nishimura, S., et al. 2017. Proc Natl Acad Sci U S A. 114: 5503-5508. PMID: 28500274
- Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment. | Boran, G., et al. 2020. Sci Rep. 10: 7827. PMID: 32385391
- Drug-Inclusive Inorganic-Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate. | Vassaki, M., et al. 2022. Molecules. 27: PMID: 36234745
- Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. | Green, JR., et al. 1994. J Bone Miner Res. 9: 745-51. PMID: 8053405
Inhibitor of:
ASM, FDPS, and MVD.Activator of:
PKC.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Zoledronic acid monohydrate, 25 mg | sc-202859 | 25 mg | $97.00 | |||
Zoledronic acid monohydrate, 100 mg | sc-202859A | 100 mg | $295.00 | |||
Zoledronic acid monohydrate, 1 g | sc-202859B | 1 g | $671.00 |